Emerald Health Therapeutics Appoints Vice President, Communications and Stakeholder Relations
18 March 2019 - 11:00PM
Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”)
(TSXV:EMH; OTCQX:EMHTF) announced today that Allan Rewak has been
appointed Vice President, Communications and Stakeholder Relations,
effective April 15, 2019.
Prior to joining Emerald, Mr. Rewak was the
Executive Director at the Cannabis Council of Canada (C3), Canada’s
national industry association for cannabis, cultivators and
processors. In the role, he unified multiple industry associations
into one collective and navigated the sector through the successful
legalisation of adult-use cannabis. For his work, the Financial
Post named him “One of the 20 Power Players Setting Down Roots in
the Cannabis Industry”.
Mr. Rewak also served as Director of
Communications and Stakeholder Relations at Newstrike Resources, a
partner at Pathway Group, and a consultant at Leonard Domino &
Associates.
“We are pleased to welcome Allan to the Emerald
team,” said Dr. Avtar Dhillon, Executive Chairman and President of
Emerald. “His deep industry relationships and proven experience in
the sector, combined with his strong background in communications
and stakeholder relations with all major relevant sectors of the
industry, are expected to augment our existing capabilities.”
Mr. Rewak has been granted an option to acquire
up to 150,000 common shares vesting over a three-year period.
About Emerald Health
Therapeutics, Inc. Emerald Health Therapeutics,
Inc. is a Canadian licensed producer of cannabis. Its 50%-owned
Pure Sunfarms joint venture in BC is completing the conversion of
its 1.1 million square foot (25 acre) greenhouse for cannabis
cultivation in the Lower Mainland and its Verdélite operation in
Québec is completing the build out of its 88,000 square feet indoor
cultivation facility. Commercial production is expanding in both
facilities. Emerald secured over 500 acres of hemp harvest in 2018
and has contracted for approximately 1000 acres in 2019 to 2022,
with the objective of extracting low-cost cannabidiol (CBD).
Emerald’s team is highly experienced in life sciences, product
development, large-scale agri-business, and marketing, and is
focused on developing proprietary, value-added cannabis products
for medical and adult-use customers. Emerald is part of the Emerald
Health group, which represents a broad array of companies focused
on developing pharmaceutical, botanical, and nutraceutical products
developed to provide wellness and medical benefits by interacting
with the human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more
information or contact:Rob Hill, Chief Financial Officer(800) 757
3536 Ext. #5
Investor Relations(800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include augmentation of capabilities; build out of the Verdalite
facility; production capacity of various facilities; and receipt of
hemp deliveries.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; failure of counterparties to perform
contractual obligations as well as the risk factors described in
the Company’s annual information form and other regulatory filings.
The forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2024 to May 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From May 2023 to May 2024